This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
GE HealthCare expects to leverage MIM Software’s imaging analytics and digital workflow capabilities across various care areas to accelerate innovation and differentiate its solutions for the benefit of patients and healthcare systems around the world.
Here is an overview of sessions, events and meetings coordinated to help members in particular specialties, sections and areas of interest learn and engage with peers and expert cardiology professionals to advance their practice, patientcare and careers. 24 Education Sessions Symposiums at ACC The “Symposiums at ACC.24”
The new FDA-cleared AI-enabled applications include the industry’s first automated tool for segmental wall motion scoring of the heart to quickly and objectively identify disorders including coronaryarterydisease and cardio-oncology issues in seconds.
Cardiovascular CT's non-invasive nature allows patients to avoid being admitted to a hospital for imaging, which makes it more convenient and patient-friendly. Invasive catheterizations, commonly employed, may fall short in identifying obstructions that prior CT imaging of the coronaries can catch.
The results of our validation studies show this innovative test demonstrates outstanding intra (2 percent) and inter (10 percent) test variation, well below the current FDA guidance (25 percent)," said Dr. David Schneider Prolocor Co-Founder and Chief Science Officer. tim.hodson Tue, 09/10/2024 - 13:34 Sept. 5,2024 - Prolocor, Inc.
Interventional cardiology has dramatically evolved over the past decades, introducing advanced techniques and tools that have revolutionized the treatment of coronaryarterydisease, valvular disorders, and structural heart diseases.
Interventional cardiology has dramatically evolved over the past decades, introducing advanced techniques and tools that have revolutionized the treatment of coronaryarterydisease, valvular disorders, and structural heart diseases.
The Role of Cardiologists Cardiologists are at the forefront of the battle against heart diseases. Their expertise covers a wide range of cardiovascular conditions, including coronaryarterydisease, heart failure, arrhythmias, and congenital heart defects.
By harnessing the power of the latest technology, healthcare providers can enhance diagnostics, treatment planning, and patientcare. With the continued evolution of AI, it is now being introduced in cardiac healthcare, promising opportunities for innovation and advancements in cardiovascular medicine. For instance: 1.
I think especially with the recent changes in guidelines and the recommendation to use CT for screening of coronaryarterydisease, we expect to see this trend really impact the way CT is used in the future.” This interdisciplinary approach is consistently contributing to more effective patientcare.
These technologies are reshaping how cardiology practices manage operations, deliver care, and enhance patient outcomes. This blog explores the profound benefits of AI and machine learning, which are revolutionizing cardiology practices, enhancing efficiency, and ultimately improving patientcare.
September 2024 Approvals Flurpiridaz F 18 Approval Date: September 27, 2024 Indication: A radioactive positron emission tomography (PET) tracer for imaging myocardial ischemia and infarction in adults with suspected or known coronaryarterydisease. To explore FDA approvals from January to July 2024, click here.
Efficient diagnosis and therapy are key elements of addressing the growing demand for care. allows clinicians to focus on what truly matters providing exceptional patientcare. These measurements are used to assess the severity of coronaryarterydisease. AltiX AI.i AltiX AI.i
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content